Nat. Rev. Urol. doi: /nrurol

Slides:



Advertisements
Similar presentations
Tyrosine kinase signalling (review) TGF signalling Notch signalling.
Advertisements

Volume 64, Issue 5, Pages (November 2013)
An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer  Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco.
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Urol. doi: /nrurol
Volume 70, Issue 5, Pages (November 2016)
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Nat. Rev. Urol. doi: /nrurol
Figure 4 Types of urinary diversion
Figure 1 Male infertility and assisted reproduction globally
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study
Nat. Rev. Urol. doi: /nrurol
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Figure 1 Cellular processes involved in cancer development
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol
Figure 2 Peptide vaccination using TAA-derived long peptides
Figure 2 Representative images from a right radical
Volume 64, Issue 5, Pages (November 2013)
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 1 Key elements of the proposed modified Delphi study
Nat. Rev. Urol. doi: /nrurol
Volume 62, Issue 1, Pages (July 2012)
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol
Figure 2 Schema for the phase II Randomized Observation versus
Figure 1 The development process of the Asian
Figure 13 Proposed management of bladder cancer with variant histology
Nat. Rev. Urol. doi: /nrurol
Figure 3 Treatment algorithm for adult infertile men with varicoceles
Figure 2 Differences between MC and AC
Figure 3 Algorithm for the determination of the clinical
to the liver and promote patient-derived xenograft tumour growth
Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT
Nat. Rev. Urol. doi: /nrurol
Figure 2 Temporal summation
Figure 6 Image sequence demonstrating coronal cuts on MRI
Nat. Rev. Urol. doi: /nrurol
Figure 2 White matter hyperintensities
Nat. Rev. Urol. doi: /nrurol
Figure 3 Template for standard pelvic lymphadenectomy
Figure 1 Comparison of LDR‑BT, HDR‑BT, and EBRT
Nat. Rev. Urol. doi: /nrurol
the SNP profile using 26 prostate cancer GWAS risk SNPs
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 6 The hexosamine biosynthetic pathway (HBP)
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 2 Logistical requirements for autologous
Figure 1 A hierarchy of steps need to be
Figure 2 The evolution of brachytherapy for prostate cancer
Nat. Rev. Urol. doi: /nrurol
Figure 4 The grey zone between active
Figure 2 Putative mechanisms of action of shockwave therapy for ED
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Figure 1 Overview of the imaging biomarker roadmap
Nat. Rev. Urol. doi: /nrurol
Figure 3 Target volume definitions
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Figure 4 Algorithm for when to determine PTEN
Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.26 Figure 5 Imaging of 65-year-old patient with prostate cancer and diffuse bone metastases Figure 5 | Imaging of 65-year-old patient with prostate cancer and diffuse bone metastases. a | Bone scintigraphy demonstrates multiple bone metastases predominantly in the pelvis and ribs. b | Corresponding maximum-intensity projection of 68Ga-PSMA–PET shows considerably more bone metastases than bone scintigraphy. PSMA, prostate-specific membrane antigen. Maurer, T. et al. (2016) Current use of PSMA–PET in prostate cancer management Nat. Rev. Urol. doi:10.1038/nrurol.2016.26